An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
Adenoviral-vectored vaccines are licensed for prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ebola virus, but, for bacterial proteins, expression in a eukaryotic cell may affect the antigen's localization and conformation or lead to unwanted glycosylation. Here, we investigated the potential use of an adenoviral-vectored vaccine platform for capsular group B meningococcus (MenB). Vector-based candidate vaccines expressing MenB antigen factor H binding protein (fHbp) were generated, and immunogenicity was assessed in mouse models, including the functional antibody response by serum bactericidal assay (SBA) using human complement. All adenovirus-based vaccine candidates induced high antigen-specific antibody and T cell responses. A single dose induced functional serum bactericidal responses with titers superior or equal to those induced by two doses of protein-based comparators, as well as longer persistence and a similar breadth. The fHbp transgene was further optimized for human use by incorporating a mutation abrogating binding to the human complement inhibitor factor H. The resulting vaccine candidate induced high and persistent SBA responses in transgenic mice expressing human factor H. The optimized transgene was inserted into the clinically relevant ChAdOx1 backbone, and this vaccine has now progressed to clinical development. The results of this preclinical vaccine development study underline the potential of vaccines based on genetic material to induce functional antibody responses against bacterial outer membrane proteins.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Science translational medicine - 15(2023), 701 vom: 21. Juni, Seite eade3901 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dold, Christina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
80295-65-4 |
|---|
| Anmerkungen: |
Date Completed 23.06.2023 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/scitranslmed.ade3901 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358445507 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358445507 | ||
| 003 | DE-627 | ||
| 005 | 20240320233218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/scitranslmed.ade3901 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM358445507 | ||
| 035 | |a (NLM)37343082 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dold, Christina |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Adenoviral-vectored vaccines are licensed for prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ebola virus, but, for bacterial proteins, expression in a eukaryotic cell may affect the antigen's localization and conformation or lead to unwanted glycosylation. Here, we investigated the potential use of an adenoviral-vectored vaccine platform for capsular group B meningococcus (MenB). Vector-based candidate vaccines expressing MenB antigen factor H binding protein (fHbp) were generated, and immunogenicity was assessed in mouse models, including the functional antibody response by serum bactericidal assay (SBA) using human complement. All adenovirus-based vaccine candidates induced high antigen-specific antibody and T cell responses. A single dose induced functional serum bactericidal responses with titers superior or equal to those induced by two doses of protein-based comparators, as well as longer persistence and a similar breadth. The fHbp transgene was further optimized for human use by incorporating a mutation abrogating binding to the human complement inhibitor factor H. The resulting vaccine candidate induced high and persistent SBA responses in transgenic mice expressing human factor H. The optimized transgene was inserted into the clinically relevant ChAdOx1 backbone, and this vaccine has now progressed to clinical development. The results of this preclinical vaccine development study underline the potential of vaccines based on genetic material to induce functional antibody responses against bacterial outer membrane proteins | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Complement Factor H |2 NLM | |
| 650 | 7 | |a 80295-65-4 |2 NLM | |
| 650 | 7 | |a Meningococcal Vaccines |2 NLM | |
| 650 | 7 | |a Antigens, Bacterial |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Carrier Proteins |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Bacterial |2 NLM | |
| 700 | 1 | |a Marsay, Leanne |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nelson |e verfasserin |4 aut | |
| 700 | 1 | |a Silva-Reyes, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Clutterbuck, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Gavin K |e verfasserin |4 aut | |
| 700 | 1 | |a Sharkey, Kelsey |e verfasserin |4 aut | |
| 700 | 1 | |a Wyllie, David |e verfasserin |4 aut | |
| 700 | 1 | |a Beernink, Peter T |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Adrian V |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Rollier, Christine S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science translational medicine |d 2009 |g 15(2023), 701 vom: 21. Juni, Seite eade3901 |w (DE-627)NLM195151879 |x 1946-6242 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:701 |g day:21 |g month:06 |g pages:eade3901 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/scitranslmed.ade3901 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 701 |b 21 |c 06 |h eade3901 | ||